SCHEMBL876331

SCHEMBL876331

Cc1cc(CO)ccc1Oc1cccc(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPAS1 Q99814 1/20 0.48
FFAR4 Q5NUL3 1/20 0.47
TTR P02766 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
MAPT P10636 1/20 0.45
NR1H2 P55055 2/20 0.44
NR1H3 Q13133 2/20 0.44
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TEAD1 P28347 3/20 0.43
PRKD3 O94806 2/20 0.43
PRKCG P05129 2/20 0.43
PRKCB P05771 2/20 0.43
PRKCA P17252 2/20 0.43
PRKCH P24723 2/20 0.43
PRKCI P41743 2/20 0.43
PRKCE Q02156 2/20 0.43
PRKCQ Q04759 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875489 0.85 AR (0.53) EPAS1TTRL3MBTL1NPSR1MAPT
SCHEMBL875557 0.85 EPAS1 (0.52) EPAS1TTRL3MBTL1NPSR1MAPT
SCHEMBL875278 0.85 EPAS1 (0.55) EPAS1TTRL3MBTL1NPSR1MAPT
SCHEMBL883499 0.85 EPAS1 (0.49) EPAS1TTRL3MBTL1NPSR1MAPT
SCHEMBL875580 0.84 FFAR1 (0.51) EPAS1TTR
SCHEMBL15278007 0.83 EPAS1 (0.47) EPAS1TTRL3MBTL1NPSR1MAPT
SCHEMBL14586640 0.81 NPSR1 (0.50) EPAS1L3MBTL1NPSR1MAPTTEAD1
SCHEMBL15096339 0.81 TTR (0.51) FFAR4TTRL3MBTL1ARALDH1A1
SCHEMBL11195440 0.81 PRKCA (0.50) EPAS1L3MBTL1NR1H2NR1H3SMN1; SMN2
SCHEMBL21731439 0.81 EPAS1 (0.48) EPAS1TTRL3MBTL1NPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
EP-2619203-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES Glaxo Group Limited (GB) 2013-07-31 EP disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 EPAS1 363/4885FFAR4 464/4885TTR 913/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 EPAS1 363/4885FFAR4 464/4885TTR 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.